Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24,443 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC; INSIGHT Investigators. Wu YL, et al. Among authors: park k. Lancet Respir Med. 2020 Nov;8(11):1132-1143. doi: 10.1016/S2213-2600(20)30154-5. Epub 2020 May 29. Lancet Respir Med. 2020. PMID: 32479794 Clinical Trial.
A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers.
Park J, Ahn YC, Kim H, Lee SH, Park SH, Lee KE, Lim DH, Park J, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K. Park J, et al. Among authors: park sh, park k. Lung Cancer. 2003 Nov;42(2):227-35. doi: 10.1016/s0169-5002(03)00282-4. Lung Cancer. 2003. PMID: 14568691 Clinical Trial.
Extrapulmonary small-cell carcinoma: a single-institution experience.
Kim JH, Lee SH, Park J, Kim HY, Lee SI, Nam EM, Park JO, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K. Kim JH, et al. Among authors: park jo, park k, park j. Jpn J Clin Oncol. 2004 May;34(5):250-4. doi: 10.1093/jjco/hyh052. Jpn J Clin Oncol. 2004. PMID: 15231859
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K. Lee J, et al. Among authors: park kw, park ys, park jo, park sh, park k. Cancer Chemother Pharmacol. 2004 Nov;54(5):385-90. doi: 10.1007/s00280-004-0837-7. Epub 2004 Jul 10. Cancer Chemother Pharmacol. 2004. PMID: 15248028 Clinical Trial.
Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K. Lim DH, et al. Among authors: park bb, park kw, park ys, park jo, park k. Cancer Chemother Pharmacol. 2005 Jul;56(1):10-4. doi: 10.1007/s00280-004-0963-2. Epub 2005 Mar 22. Cancer Chemother Pharmacol. 2005. PMID: 15782313 Clinical Trial.
24,443 results
You have reached the last available page of results. Please see the User Guide for more information.